Home » News » 12/05 » Bayer doubles sales forecast for Nexavar

Bayer doubles sales forecast for Nexavar

Date published: 08/12/2005

German pharmaceutical firm, Bayer, has doubled the sales estimate for its experimental cancer drug Nexavar. Speaking to analysts in London the company said that the drug is in the last stage of tests required to sell the drug for lung cancer, and it has also been lodged with regulators as a treatment for kidney cancer.

It is predicted that the drug, developed with Onyx Pharmaceuticals, will produce annual sales of more than 1 billion euros ($1.2 billion) at its peak. Bayer also said blood-clotting agent Kogenate would raise higher than expected sales and upped its forecast to more than 1 billion euros. The drug is already Bayer's biggest- selling health-care product.

Trasylol, used with Kogenate in open heart surgery, may bring in more than 500 million euros a year, the company said.

© Adfero Ltd

Disclaimer

AllAboutMedicalSales excludes any warranty, express or implied, as to the quality, accuracy, timeliness, completeness or fitness for a particular purpose of this briefing. AllAboutMedicalSales will not be liable for any claims, penalties, losses, damages, costs, or expenses arising from the use of or inability to use this briefing or from any unauthorised access to or alteration of the Briefing. AllAboutMedicalSales makes no warranty that the contents of this briefing are compatible with all computer systems and browsers.